NCT06631079 — NEC NECVAX neoantigen vaccine trial
Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors
Registry record
| Registry ID | NCT06631079 ↗ |
|---|---|
| Lead sponsor | NEC Bio B.V |
| Collaborators | NEC Bio Therapeutics |
| Phase | Phase 1/2 |
| Status | Active Not Recruiting |
| Indication | Solid Tumor |
| Enrollment | 20 participants (target) |
| Start date | 2024-10-07 |
| Primary completion | 2026-07-31 (est.) |
| Last registry update | 8 Jan 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT06631079), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT06631079?
NCT06631079 (Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors) is registered on ClinicalTrials.gov as Phase 1/2, sponsored by NEC Bio B.V.
Is NCT06631079 recruiting?
As of the 2026-01-08 registry update, NCT06631079 is listed as "Active Not Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT06631079?
The lead sponsor is NEC Bio B.V. Collaborators: NEC Bio Therapeutics.
What condition does NCT06631079 study?
The registered condition is Solid Tumor. Primary completion is listed as 2026-07-31 (estimated).
Are results available for NCT06631079?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT06631079.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.